Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
about
Pregnane X receptor- and CYP3A4-humanized mouse models and their applications.Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora.Gene Perturbation Atlas (GPA): a single-gene perturbation repository for characterizing functional mechanisms of coding and non-coding genesCoadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of miceOral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorptionSurface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism."Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.P-gp and taxanes.Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.Verapamil and rifampin effect on p-glycoprotein expression in hepatocellular carcinoma.Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats.Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.Effects of cysteine on the pharmacokinetics of docetaxel in rats with protein-calorie malnutrition.Effects of cysteine on the pharmacokinetics of tamoxifen in rats with protein-calorie malnutrition.From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats.Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends.A network pharmacology approach to explore the mechanisms of Erxian decoction in polycystic ovary syndrome
P2860
Q35005644-FDF45B19-DA2F-4F65-8FFC-66A9B7897F89Q36105337-7F17286F-C71B-4E4E-BD4B-87DF3CBFEA71Q36293551-9A46CA03-030E-470E-BD2B-501B699D7833Q36411053-D64879C0-E257-4739-87A7-76A089D7C555Q37256120-D8EA4E77-F4AC-4B6F-9813-CAD55BF7B3F6Q37490613-69F2F81B-50FB-4FC3-947C-C5A52F20EC5BQ38183877-467BC40B-22F3-46E3-A9AB-F2637E51CF35Q38970000-D7656923-F78C-43B6-B586-CCCDD3E30182Q40036535-58DCC9A7-4579-41C4-B4B8-1606C6C29858Q40617502-B64875BD-6B6A-4619-82F4-2F189958B62DQ41195857-6901C5F4-96CF-42AA-B695-141BE203D183Q41882199-3B3277D7-3D49-44F0-9EB1-6B97D99C3D8DQ41889792-BB24636E-C549-4D82-A6DE-FFB823424D71Q42173807-1E7C1306-13FA-4FA4-BA5E-FC6E6175BAD6Q42429561-FE9DE1EA-DD91-4098-BD9B-7B16595EF432Q42956071-805600D6-1DC4-4E6E-8440-730F96B59C79Q43028970-70285300-7444-4629-AEB6-429643BA1774Q43567242-72173C80-535B-406E-86FB-7CFA5A05CF48Q44693895-B0CE9EF6-015D-4A9C-915D-F1B75C197313Q45162147-3513A12C-0212-4B75-947D-2DD1B30DA183Q48389089-28EEFF5C-8963-4767-985A-FB07BD23892CQ54207094-B55998E9-395B-4B2E-B23F-213F65EA65FFQ55278614-5DDD110E-23BF-4E62-A2BD-24E1CE4A4F12Q58696673-4754F24C-21EF-4A65-B75C-AB091C3E8C01
P2860
Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Absence of both cytochrome P45 ...... d risk of intestinal toxicity.
@en
Absence of both cytochrome P45 ...... d risk of intestinal toxicity.
@nl
type
label
Absence of both cytochrome P45 ...... d risk of intestinal toxicity.
@en
Absence of both cytochrome P45 ...... d risk of intestinal toxicity.
@nl
prefLabel
Absence of both cytochrome P45 ...... d risk of intestinal toxicity.
@en
Absence of both cytochrome P45 ...... d risk of intestinal toxicity.
@nl
P2093
P1433
P1476
Absence of both cytochrome P45 ...... d risk of intestinal toxicity.
@en
P2093
Alfred H Schinkel
Antonius E van Herwaarden
Cornelia M M van der Kruijssen
Els Wagenaar
Hilde Rosing
Ji-Ying Song
Jos H Beijnen
Jurjen S Lagas
Olaf van Tellingen
Robert A B van Waterschoot
P304
P356
10.1158/0008-5472.CAN-09-2915
P407
P577
2009-11-17T00:00:00Z